Literature DB >> 18259841

Chemoresistance in gliomas.

Chen Lu1, Amal Shervington.   

Abstract

Despite improved knowledge and advanced treatments of gliomas, the overall survival rate for glioma patients remains low. Gliomas comprise of significant cell heterogeneity that contains a large number of multidrug resistant (MDR) phenotypes and cancer stem cells (CSCs), a combination that may contribute to the resistance to treatment. This article reviews the MDR related genes, major-vault protein (MVP), anti-apoptotic protein (Bcl-2) and the molecular mechanisms that may contribute to chemoresistance, in addition to the upregulated MDR phenotypes present in CSCs that has recently been identified in gliomas. Moreover, future potential therapies that modulate MDR phenotypes and CSCs are also reviewed. An improved understanding of MDR may lead to a combined treatment, targeting both CSCs and their protective MDR phenotypes leading eventually to attractive strategies for the treatment of gliomas.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18259841     DOI： 10.1007/s11010-008-9722-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN： 0300-8177            Impact factor:   3.396


  100 in total

Review 1.  ABC transporter architecture and regulatory roles of accessory domains.

Authors:  Esther Biemans-Oldehinkel; Mark K Doeven; Bert Poolman
Journal:  FEBS Lett       Date:  2005-12-12       Impact factor: 4.124

2.  The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry.

Authors:  D C Huang; L A O'Reilly; A Strasser; S Cory
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

Review 3.  Cancer stem cells: lessons from leukemia.

Authors:  Jean C Y Wang; John E Dick
Journal:  Trends Cell Biol       Date:  2005-09       Impact factor: 20.808

4.  BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.

Authors:  Courtney Greider; Anuja Chattopadhyay; Christina Parkhurst; Elizabeth Yang
Journal:  Oncogene       Date:  2002-11-07       Impact factor: 9.867

5.  Membrane properties of rat embryonic multipotent neural stem cells.

Authors:  Jingli Cai; Aiwu Cheng; Yongquan Luo; Chengbiao Lu; Mark P Mattson; Mahendra S Rao; Katsutoshi Furukawa
Journal:  J Neurochem       Date:  2004-01       Impact factor: 5.372

6.  Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.

Authors:  Alice B Brown; Wendy Yang; Nils O Schmidt; Rona Carroll; Kim K Leishear; Nikolai G Rainov; Peter M Black; Xandra O Breakefield; Karen S Aboody
Journal:  Hum Gene Ther       Date:  2003-12-10       Impact factor: 5.695

7.  Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mRNA.

Authors:  Marion Rittierodt; Thomas Tschernig; Kunyu Harada
Journal:  Pathobiology       Date:  2004       Impact factor: 4.342

8.  Reduction of expression of the multidrug resistance protein (MRP)1 in glioma cells by antisense phosphorothioate oligonucleotides.

Authors:  Yoshihito Matsumoto; Keisuke Miyake; Katsuzou Kunishio; Takashi Tamiya; Nagao Seigo
Journal:  J Med Invest       Date:  2004-08

9.  Expression of Bcl2 proto-oncogene in primary tumors of the central nervous system.

Authors:  D Tyagi; B S Sharma; S K Gupta; D Kaul; R K Vasishta; V K Khosla
Journal:  Neurol India       Date:  2002-09       Impact factor: 2.117

10.  Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001.

Authors:  M P Coleman; B Rachet; L M Woods; E Mitry; M Riga; N Cooper; M J Quinn; H Brenner; J Estève
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  54 in total

1.  Expression of the Major Vault Protein (MVP) and Cellular Vault Particles in Fish.

Authors:  Alyssa L Margiotta; Lisa J Bain; Charles D Rice
Journal:  Anat Rec (Hoboken)       Date:  2017-07-20       Impact factor: 2.064

Review 2.  The role of AEG-1/MTDH/LYRIC in the pathogenesis of central nervous system disease.

Authors:  Evan K Noch; Kamel Khalili
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

3.  Pro-apoptotic and anti-angiogenic properties of the α /β-thujone fraction from Thuja occidentalis on glioblastoma cells.

Authors:  Angelo Torres; Yosselyn Vargas; Daniel Uribe; Cristian Carrasco; Cristian Torres; René Rocha; Carlos Oyarzún; Rody San Martín; Claudia Quezada
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

4.  Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes.

Authors:  Weiliang Chen; Donghai Wang; Xinwen Du; Ying He; Songyu Chen; Qianqian Shao; Chao Ma; Bin Huang; Anjing Chen; Peng Zhao; Xun Qu; Xingang Li
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

5.  Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.

Authors:  Maroulio Talieri; Marita Zoma; Marina Devetzi; Andreas Scorilas; Alexandros Ardavanis
Journal:  Tumour Biol       Date:  2012-04-03

6.  Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation.

Authors:  David Díaz-Carballo; Sebastian Gustmann; Holger Jastrow; Ali Haydar Acikelli; Philip Dammann; Jacqueline Klein; Ulrike Dembinski; Walter Bardenheuer; Sascha Malak; Marcos J Araúzo-Bravo; Beate Schultheis; Constanze Aldinger; Dirk Strumberg
Journal:  DNA Cell Biol       Date:  2014-08-15       Impact factor: 3.311

Review 7.  Hedgehog signalling in breast cancer.

Authors:  Maria Kasper; Viljar Jaks; Marie Fiaschi; Rune Toftgård
Journal:  Carcinogenesis       Date:  2009-02-23       Impact factor: 4.944

Review 8.  Brain tumor stem cells as therapeutic targets in models of glioma.

Authors:  Dan Richard Laks; Koppany Visnyei; Harley Ian Kornblum
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

9.  REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.

Authors:  Huibo Wang; Shu-Yu Zhang; Shuai Wang; Juan Lu; Wenting Wu; Lin Weng; Dan Chen; Yu Zhang; Zhipeng Lu; Jingmin Yang; Yuanyuan Chen; Xu Zhang; Xiaofeng Chen; Caihua Xi; Daru Lu; Shiguang Zhao
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

Review 10.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.

Authors:  Dimitry A Chistiakov; Vladimir P Chekhonin
Journal:  Tumour Biol       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.